West Pharmaceutical Services, Inc. Common Stock (WST)

West Pharmaceutical Services (NYSE:WST) reported third-quarter results that exceeded its expectations, driven by continued demand for high-value product components, including those used in GLP-1 therapies and biologics. The company raised its full-year revenue and adjusted earnings outlook following

Healthcare products company West Pharmaceutical Services (NYSE:WST) announced better-than-expected revenue in Q3 2026, with sales up 8.7% year on year to $87...

GLP-1 demand drives HVP components to 53% of revenue with 20% organic growth.

Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q3 2026 results exceeding the market’s revenue expectations, with revenue up 8.7...

Healthcare products company West Pharmaceutical Services (NYSE:WST) will be announcing earnings results this Thursday morning. Here’s what to expect. West Ph...

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. Lu...

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorab...

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco...

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have be...

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg...

West Pharmaceutical Services has been on fire lately. In the past six months alone, the company’s stock price has rocketed 43%, reaching $339.52 per share. T...

West Pharmaceutical Services posted a solid Q2, with revenue and adjusted earnings per share exceeding Wall Street expectations, while the market response re...

What Happened? A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HC...

Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 13....

West Pharmaceutical Services (NYSE:WST) raised its full-year 2026 outlook after reporting second-quarter results that topped management’s expectations, supported by strong demand for high-value product components, biologics-related offerings and GLP-1 elastomers. Chief Executive Officer and Board C